Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
